
Opinion|Videos|August 23, 2024
Management of Comment Adverse Effects Associated with mCRPC Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Advertisement
Episodes in this series

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5

















